Fresenius Medical Care AG & Co. (NYSE:FMS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Fresenius has had a disappointing run on the bourse over the last six months. However, a solid full-year guidance instills our confidence on the stock. We believe this is in tune with the ‘Growth Strategy 2020’, under which it aims to boost revenues to $28 billion by 2020, corresponding to an average annual growth rate of around 10%. A wide range of dialysis products, initiatives to gain market traction, strengthened international foothold, strategic acquisitions and divestments act as major catalysts.On the flipside, lackluster performance by the renal pharmaceutical segment is likely to dent Latin-American revenues in the coming quarters. Having a strong international foothold, Fresenius faces the brunt of stringent regulations in almost every country in which it operates. Thus, it has to fulfill specific legal requirements that include tough antitrust laws. Regulatory hurdles and competition in the niche markets are major headwinds.”

Other analysts have also issued reports about the company. Morgan Stanley lowered Fresenius Medical Care AG & Co. from an “overweight” rating to an “equal weight” rating in a research note on Monday, December 11th. DZ Bank reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Monday, December 18th. Nord/LB reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Wednesday, December 27th. UBS Group upgraded Fresenius Medical Care AG & Co. from a “sell” rating to a “neutral” rating in a research note on Thursday, January 4th. Finally, SunTrust Banks set a $62.00 price objective on Fresenius Medical Care AG & Co. and gave the company a “buy” rating in a research note on Thursday, December 21st. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $55.67.

Shares of Fresenius Medical Care AG & Co. (NYSE FMS) traded down $0.11 on Tuesday, hitting $54.53. The company’s stock had a trading volume of 179,600 shares, compared to its average volume of 158,767. The company has a market capitalization of $33,510.00, a price-to-earnings ratio of 21.90, a PEG ratio of 2.27 and a beta of 0.45. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.98 and a current ratio of 1.22. Fresenius Medical Care AG & Co. has a 52-week low of $40.02 and a 52-week high of $55.30.

Fresenius Medical Care AG & Co. (NYSE:FMS) last issued its earnings results on Thursday, November 2nd. The company reported $0.59 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.61 by ($0.02). Fresenius Medical Care AG & Co. had a net margin of 7.04% and a return on equity of 11.51%. equities analysts forecast that Fresenius Medical Care AG & Co. will post 2.37 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FMS. UBS Asset Management Americas Inc. raised its position in Fresenius Medical Care AG & Co. by 3.6% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock valued at $114,000 after purchasing an additional 81 shares during the last quarter. YorkBridge Wealth Partners LLC grew its position in Fresenius Medical Care AG & Co. by 19.4% in the second quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock worth $222,000 after acquiring an additional 749 shares in the last quarter. Stifel Financial Corp purchased a new position in Fresenius Medical Care AG & Co. in the second quarter worth about $225,000. Raymond James Financial Services Advisors Inc. purchased a new position in Fresenius Medical Care AG & Co. in the third quarter worth about $239,000. Finally, Pacer Advisors Inc. grew its position in Fresenius Medical Care AG & Co. by 37.6% in the third quarter. Pacer Advisors Inc. now owns 5,105 shares of the company’s stock worth $250,000 after acquiring an additional 1,394 shares in the last quarter. 3.03% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Fresenius Medical Care AG & Co. (FMS) Downgraded by Zacks Investment Research to Hold” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/16/fresenius-medical-care-ag-co-fms-downgraded-by-zacks-investment-research-to-hold.html.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care AG & Co. (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.